EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study

Ilya Tsimafeyeu iD, Vyacheslav Chubenko, Olga Baklanova, Alexey Kalpinskiy, Sufia Safina, Andrei Lebedinets iD, Vladislav Petkau iD, Elvira Parsadanova, Maria Turganova, Aleksei Shkurat iD, Natalia Tovbik, Elena Tkacheva und 5 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol32010011 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, 2024. Verfasst von Ilya Tsimafeyeu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Bureau for Cancer Research-BUCARE, Moscow Office, 125047 Moscow, Russia. Hauptthemen laut MEDLINE: Axitinib, Carcinoma, Renal Cell, Kidney Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bureau of Cancer Research—BUCARE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC).

Methods

RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety.

Results

A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%).

Conclusions

Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AxitinibCarcinoma, Renal CellKidney NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedMaleFemaleAgedAdultRetrospective StudiesNeoplasm MetastasisTreatment OutcomeAged, 80 and overProspective Studies

Stichwörter der Autor:innen

RAVE-Renal ambispective studyavelumab plus axitinibfirst-line therapymetastatic renal cell carcinoma

Substanzen

AxitinibavelumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Bureau for Cancer Research-BUCARE, Moscow Office, 125047 Moscow, Russia.
  • Saint-Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care Oncological, 197110 Saint-Petersburg, Russia.
  • Irkutsk Regional Cancer Center, 664048 Irkutsk, Russia.
  • P.A. Hertsen Moscow Oncology Research Center-National Medical Research Center of Radiology, 125284 Moscow, Russia.
  • Republican Dispensary of Tatarstan, 420029 Kazan, Russia.
  • SBHI Leningrad Regional Clinical Hospital, 194291 Saint-Petersburg, Russia.

ORCID-Profile: Ilya Tsimafeyeu, Andrei Lebedinets, Vladislav Petkau, Aleksei Shkurat

Förderung

  • Bureau of Cancer Research—BUCARE

Zitieren

APA

Tsimafeyeu, I., Chubenko, V., Baklanova, O., Kalpinskiy, A., Safina, S., Lebedinets, A., Petkau, V., Parsadanova, E., Turganova, M., Shkurat, A., Tovbik, N., Tkacheva, E., Anzhiganova, Y., Novikova, O., Bragina, V., Zukov, R., & Orlova, R. (2024). Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study. Current Oncology. https://doi.org/10.3390/curroncol32010011

Vancouver

Tsimafeyeu I, Chubenko V, Baklanova O, Kalpinskiy A, Safina S, Lebedinets A, et al. Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study. Current Oncology. 2024. doi:10.3390/curroncol32010011

BibTeX
@article{Tsimafeyeu2024,
  author = {Tsimafeyeu, Ilya and Chubenko, Vyacheslav and Baklanova, Olga and Kalpinskiy, Alexey and Safina, Sufia and Lebedinets, Andrei and Petkau, Vladislav and Parsadanova, Elvira and Turganova, Maria and Shkurat, Aleksei and Tovbik, Natalia and Tkacheva, Elena and Anzhiganova, Yulia and Novikova, Olga and Bragina, Varvara and Zukov, Ruslan and Orlova, Rashida},
  title = {Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol32010011}
}
Kostenlos starten →